Strategic partnership with Boca Biolistics

Oxford BioDynamics Plc

Oxford BioDynamics announces strategic partnership with Boca Biolistics in order to advance EpiSwitch™ disease severity program for COVID-19

·    Highly diverse samples will enable development of world's first 3D genomics prognostic immune health test for disease severity

·    US-based specialty lab and biorepository, Boca Biolistics, to provide highly diverse Covid-19 samples, including those from hardest hit territories, such as Peru, and for "long COVID"

Oxford, UK - 2 November 2020 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing personalized medicine tests based on 3D genomics, has entered into a strategic partnership with Boca Biolistics, a US-based biorepository, reference lab and Contract Research Organization (CRO).

Under the terms of the agreement, Oxford BioDynamics will receive a diverse range of blood samples from COVID-19 patients, with detailed clinical information on disease severity. These will add to Oxford BioDynamics' existing database of 500+ UK and US samples. Financial details of the partnership are not disclosed.

Oxford BioDynamics requires the widest diversity of samples as possible, depicting the broadest possible range of severity levels expressed in patients, to support product development of its EpiSwitch™ prognostic immune-response test. Therefore, Boca Biolistics is prospectively procuring samples for Oxford Biodynamics from the US and the Caribbean, as well as South America.

The underlying aim of Oxford BioDynamics is the development of a disease severity test leveraging off the Company's proprietary EpiSwitch™ technology.  The 3D structure of a patient's genome contains over 1 million molecular regulatory data points¹. These can be interrogated from a patient's blood using the EpiSwitch™ technology to determine what makes certain patients particularly vulnerable to hyperinflammation and severe side effects when exposed to Covid-19 infection. Based on this data, the Company is developing a panel of risk profiles to offer commercial tests that will facillitate the assessment of individual risk levels and assist with patient prognoses.

Boca Biolistics brings decades of expertise in infectious and tropical disease research and has driven the advancement of diagnostic technologies for viral infections such as HIV and Zika² by procuring specimens from around the world for commercial product development and the advancement of precision medicine. It is a hybrid CRO with an integrated life science biorepository, offering central laboratory testing as well as clinical trial services. 

OBD is currently working with severe and mild sample cohorts procured from Peru. Currently, Peru has the highest mortality COVID-19 rate (over 100 per 100,000 inhabitants)³ to date, surpassing Brazil as well as Chile. In addition to these samples, Boca Biolistics will procure longitudinal cohorts observing the same patients over time, to enable prognostic insights into "long COVID". This condition is a serious complication for patients who have recovered from initial infection, but then relapse with symptoms such as profound fatigue, breathlessness, muscle aches or cognitive impairments.

Valentin Adia, Chief Development Officer, Boca Biolistics said: "With the expertise Boca Biolistics has developed from our involvement in other global viral outbreaks, including Zika, we look forward to contributing our know-how in infectious disease management, laboratory testing, and clinical trial services to Oxford BioDynamics in the broader effort to respond to COVID-19. We believe our expertise in some of the hardest hit territories such as Peru will be especially key." 

Dr. Jon Burrows, CEO of Oxford BioDynamics commented: "Working with an established integrated industry partner is another step on the path to commercializing our disease severity program for COVID-19. Boca Biolistics has a global footprint and a proven track record for delivering high-quality annotated samples and supporting frontline test developments and deployment.

He added, "This strategic partnership follows quickly on from the recent agreement with the prestigious Oregon Health & Science University which has provided us with COVID-19 samples for our product development. It is the range of samples we are accumulating which will enable us to create a detailed understanding of how the 3D genomic structure of our DNA determines our immune health. This in turn will provide a powerful basis for our forthcoming EpiSwitch™ test."

With the COVID-19 pandemic affecting people worldwide, understanding how individual risk of disease severity is reflected is critical. Advanced forecasting of an individual's risk of disease severity will be beneficial for healthcare settings in terms of devising workforce risk mitigation strategies and the optimization of acute and long-term treatment decisions. This knowledge is especially important for high-risk workforces, essential workers, and frontline healthcare providers. 

1.        https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/OBD-EpiSwitch-Biomarker-Workflow-June-2020-US-2.pdf

2.        Steinhagen K, Probst C, Radzimski C, et al. Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016;21(50):pii=30426.

3.        https://www.who.int/publications/m/item/weekly-epidemiological-update---27-october-2020

- ENDS -

FOR MORE INFORMATION:

NOTES TO EDITORS:

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programs, enabling the personalization of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit our website, www.oxfordbiodynamics.com, or follow us on Twitter or LinkedIn.